Weight Wellness for the PCP: The Next Generation of Anti-Obesity Medications

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Weight Wellness for the PCP: The Next Generation of Anti-Obesity Medications

By University of Texas Southwestern Medical Center FEATURING Jaime Almandoz

835 views

April 2, 2024

Disclaimer: On November 8, 2023 the FDA approved Zepbound (tirzepatide) injection for chronic weight management ...
read more ↘ in adults with obesity (body mass index of 30 kilograms per square meter (kg/ m2) or greater) or overweight (body mass index of 27 kg/m2 or greater) with at least one weight-related condition (such as high blood pressure, type 2 diabetes or high cholesterol) for use, in addition to a reduced calorie diet and increased physical activity.
↖ read less

2 Comments